Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

K Fizazi; G Kramer; JC Eymard; CN Sternberg; J De Bono; D Castellano; B Tombal; C Whulfing; M Liontos; J Carles; R Iacovelli; B Melichar; A Sverrisdottir; C Theodore; S Feyerabend; C Helissey; S Oudard; G Facchini; EM Poole; A Ozatilgan; C Geffriaud-Ricouard; S Bensfia; Ronald de Wit

doi:10.1016/s1470-2045(20)30449-6

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

K Fizazi, G Kramer, JC Eymard, CN Sternberg, J De Bono, D Castellano, B Tombal, C Whulfing, M Liontos, J Carles, R Iacovelli, B Melichar, A Sverrisdottir, C Theodore, S Feyerabend, C Helissey, S Oudard, G Facchini, EM Poole, A OzatilganC Geffriaud-Ricouard, S Bensfia, Ronald de Wit

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

32 Citations (Scopus)

Original language	English
Pages (from-to)	1513-1525
Number of pages	13
Journal	Lancet Oncology
Volume	21
Issue number	11
DOIs	https://doi.org/10.1016/s1470-2045(20)30449-6
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s1470-2045(20)30449-6

http://hdl.handle.net/1765/131631

Cite this

Fizazi, K., Kramer, G., Eymard, JC., Sternberg, CN., De Bono, J., Castellano, D., Tombal, B., Whulfing, C., Liontos, M., Carles, J., Iacovelli, R., Melichar, B., Sverrisdottir, A., Theodore, C., Feyerabend, S., Helissey, C., Oudard, S., Facchini, G., Poole, EM., ... de Wit, R. (2020). Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncology, 21(11), 1513-1525. https://doi.org/10.1016/s1470-2045(20)30449-6

@article{5fe2d06f9d36455eab424e790199991e,

title = "Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study",

author = "K Fizazi and G Kramer and JC Eymard and CN Sternberg and {De Bono}, J and D Castellano and B Tombal and C Whulfing and M Liontos and J Carles and R Iacovelli and B Melichar and A Sverrisdottir and C Theodore and S Feyerabend and C Helissey and S Oudard and G Facchini and EM Poole and A Ozatilgan and C Geffriaud-Ricouard and S Bensfia and {de Wit}, Ronald",

year = "2020",

doi = "10.1016/s1470-2045(20)30449-6",

language = "English",

volume = "21",

pages = "1513--1525",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "11",

}

Fizazi, K, Kramer, G, Eymard, JC, Sternberg, CN, De Bono, J, Castellano, D, Tombal, B, Whulfing, C, Liontos, M, Carles, J, Iacovelli, R, Melichar, B, Sverrisdottir, A, Theodore, C, Feyerabend, S, Helissey, C, Oudard, S, Facchini, G, Poole, EM, Ozatilgan, A, Geffriaud-Ricouard, C, Bensfia, S & de Wit, R 2020, 'Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study', Lancet Oncology, vol. 21, no. 11, pp. 1513-1525. https://doi.org/10.1016/s1470-2045(20)30449-6

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. / Fizazi, K; Kramer, G; Eymard, JC et al.
In: Lancet Oncology, Vol. 21, No. 11, 2020, p. 1513-1525.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

AU - Fizazi, K

AU - Kramer, G

AU - Eymard, JC

AU - Sternberg, CN

AU - De Bono, J

AU - Castellano, D

AU - Tombal, B

AU - Whulfing, C

AU - Liontos, M

AU - Carles, J

AU - Iacovelli, R

AU - Melichar, B

AU - Sverrisdottir, A

AU - Theodore, C

AU - Feyerabend, S

AU - Helissey, C

AU - Oudard, S

AU - Facchini, G

AU - Poole, EM

AU - Ozatilgan, A

AU - Geffriaud-Ricouard, C

AU - Bensfia, S

AU - de Wit, Ronald

PY - 2020

Y1 - 2020

U2 - 10.1016/s1470-2045(20)30449-6

DO - 10.1016/s1470-2045(20)30449-6

M3 - Article

SN - 1470-2045

VL - 21

SP - 1513

EP - 1525

JO - Lancet Oncology

JF - Lancet Oncology

IS - 11

ER -